Navigation Links
Opsona Therapeutics Closes EUR18M Funding
Date:2/18/2009

anised monoclonal antibody (OPN-305) to a key toll-like receptor (TLR) target, has demonstrated efficacy in a number of animal models and will start pivotal clinical trials in 2010.

Florent Gros, managing director, Novartis Venture Fund added, "We are delighted to be working with Opsona Therapeutics and the other investors to assist Opsona in progressing the company's highly innovative technology and approaches towards the clinic. The innate immune system represents a new frontier in targeting inflammatory diseases, and the caliber of the investors in this funding round is a demonstration of Opsona's expertise and capabilities in this highly promising field.'

Opsona has also announced the opening of a new facility in Switzerland. The Swiss laboratory will carry out pivotal assay development and biochemical work for new projects and therapeutics recently acquired by Opsona to expand its pipeline of immunomodulators. The expertise that it intends to grow in Switzerland will complement the existing team and activity in Dublin.

Dr Cormac Kilty, Chairman of Opsona and past Chairman of the Irish Bioindustry Association explains "This is major achievement for any biotechnology company in the current economic climate. Opsona's R&D shows that emerging Irish companies can reach international recognition in biotechnology."

Notes to Editors:

About Opsona Therapeutics

Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 with three of Trinity College Dublin's respected Immunologists (Professors Luke O'Neill, Kingston Mills and Dermot Kelleher). The company is specifically interested in drugs which modulate the innate immune system and its signalling, specifically Toll-Like Receptors (TLR). Opsona has a pipeline of therapeutics in advanced pre-clini
'/>"/>

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Knowledgent , the data and ... the potential of big data analytics in the life ... to help life sciences and healthcare organizations understand the ... critical business insights. , The life sciences and healthcare ... by patient profiling, compliance and regulatory requirements, and scientific ...
(Date:5/22/2015)... DALLAS , May 22, 2015 Baylor ... and the Translational Genomics Research Institute (TGen) in ... that will focus on accelerating early detection and treatments for ... science of both institutions will lead to new clinical trials ... therapies – bridging the gap from bench to bedside across ...
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)... 2015 Seventh Wave Laboratories, a consulting-based ... of pharmaceutical products and medical devices, announced the purchase ... a 50,000 sq. ft. building more than three times ... growth. Facility renovations will begin immediately and the gradual ... occur in September. , “We are excited about ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3
... 22 Techne Corporation,s,(Nasdaq: TECH ) consolidated net ... to $28.6 million or $.74 per diluted share,compared with ... quarter ended,September 30, 2007. Net earnings as a percentage ... of last year to 41.2% for the quarter ended,September ...
... Inc.,(Nasdaq: MDVN ) today announced that the ... its collaboration with,Pfizer Inc. expired on October 20, ... to jointly develop and commercialize,Dimebon for the treatment ... waiting period triggers an up-front payment to Medivation,of ...
... ,silent killers, such as ... Screenings provide potentially life-saving data, including actual images ... and their doctors ... Oct. 22 HealthYes!(TM), based in Austin,is a premier ...
Cached Biology Technology:Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 5Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 3HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 4HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 5HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 6HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 7
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... (March 14, 2012) A research team has identified ... in gene expression, within reprogrammed skin cells. These signatures ... reprogrammed skin cells or induced pluripotent stem cells (iPSCs), ... how the expression of the protein is controlled brings ...
... A new research survey conducted by the Center for ... Center shows the Bangladeshi community in New York City experiences ... and lack of diabetes awareness. The study, published in the ... Health , also found the Bangladeshi community has an interest ...
... Scientists at Johannes Gutenberg University Mainz (JGU) in ... proteins. Detailed knowledge of the dynamics of proteins is ... that occur on the molecular level. To date, this ... with fluorescent substances, but unfortunately this changes the proteins ...
Cached Biology News:Epigenetic signatures direct the repair potential of reprogrammed cells 2New study shines light on barriers to diabetes care in NYC Bangladeshi community 2Gold nanoantennas detect proteins 2
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Request Info...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: